---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009894"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:05.431069+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026

## Summary
- Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.
- SPY001 enrollment complete ahead of schedule; SKYLINE Part A readouts now expected to begin Q2 2026.
- Six total proof-of-concept readouts planned: 3 from SKYLINE (UC) and 3 from SKYWAY (RA, PsA, axSpA) by 4Q 2026.
- Pro forma cash $783M as of Sept 30, 2025, including Oct 2025 offering net proceeds; runway into H2 2028.

## SEC filing metadata
- accession: 0001193125-26-009894
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312526009894/0001193125-26-009894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312526009894/d28401d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009894
- JSON: https://secwatch.observer/filing/0001193125-26-009894.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.